Home
  >  
Section 13
  >  
Chapter 12,411

Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301

Takenaka, T.; Itoh, K.; Suzuki, T.; Utsunomiya, A.; Matsuda, S.; Chou, T.; Sai, T.; Sano, M.; Konda, S.; Ohno, T.; Mikuni, C.; Deura, K.; Yamada, T.; Mizorogi, F.; Nagoshi, H.; Tomonaga, M.; Hotta, T.; Kawano, K.; Tsushita, K.; Hirano, M.; Shimoyama, M.

International Journal of Hematology 79(2): 165-173

2004


ISSN/ISBN: 0925-5710
PMID: 15005346
DOI: 10.1532/ijh97.03115
Accession: 012410539

To investigate whether combination chemotherapy with vincristine, cyclophosphamide, prednisolone, and melphalan (COP/MP) with the addition of ranimustine (MCNU) (MCNU-COP/MP) is superior to the slightly modified COP/MP (mCOP/MP) regimen in multiple myeloma (MM), a multicenter randomized study was performed.

PDF emailed within 0-6 h: $19.90